These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 28328761)

  • 1. Drug Efficacy Monitoring in Pharmacotherapy of Multiple Sclerosis With Biological Agents.
    Caldano M; Raoul W; Rispens T; Bertolotto A
    Ther Drug Monit; 2017 Aug; 39(4):350-355. PubMed ID: 28328761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Biological treatment of multiple sclerosis].
    Sørensen PS; Sellebjerg F
    Ugeskr Laeger; 2008 Jun; 170(24):2156-9. PubMed ID: 18565303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis.
    Sørensen PS
    J Neurol Sci; 2011 Dec; 311 Suppl 1():S29-34. PubMed ID: 22206763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States.
    Bonafede MM; Johnson BH; Wenten M; Watson C
    Clin Ther; 2013 Oct; 35(10):1501-12. PubMed ID: 24139422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts.
    Berger T; Elovaara I; Fredrikson S; McGuigan C; Moiola L; Myhr KM; Oreja-Guevara C; Stoliarov I; Zettl UK
    CNS Drugs; 2017 Jan; 31(1):33-50. PubMed ID: 27882532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Disease modifying drugs in multiple sclerosis and pregnancy].
    Tur C; Tintoré M; Aguilera C
    Med Clin (Barc); 2012 Sep; 139(7):316-8. PubMed ID: 22743277
    [No Abstract]   [Full Text] [Related]  

  • 7. INNOVATIVE THERAPIES REDEFINE TREATMENT GOALS IN MULTIPLE SCLEROSIS.
    Lazibat I; Šamija RK; Rotim K
    Acta Clin Croat; 2016 Mar; 55(1):125-33. PubMed ID: 27333728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Ocular Manifestations of Drugs Used to Treat Multiple Sclerosis.
    Heath G; Airody A; Gale RP
    Drugs; 2017 Mar; 77(3):303-311. PubMed ID: 28181178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Highly active multiple sclerosis: options for monoclonal antibody therapy].
    Khachanova NV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(10. Vyp. 2):49-57. PubMed ID: 31934988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on disease-modifying therapies for multiple sclerosis.
    Vargas DL; Tyor WR
    J Investig Med; 2017 Jun; 65(5):883-891. PubMed ID: 28130412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current and future role of interferon beta in the therapy of multiple sclerosis.
    Farrell RA; Giovannoni G
    J Interferon Cytokine Res; 2010 Oct; 30(10):715-26. PubMed ID: 20874249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Agents for Relapsing Forms of Multiple Sclerosis.
    Straus Farber R; Harel A; Lublin F
    Annu Rev Med; 2016; 67():309-21. PubMed ID: 26394285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Established and novel disease-modifying treatments in multiple sclerosis.
    Cross AH; Naismith RT
    J Intern Med; 2014 Apr; 275(4):350-63. PubMed ID: 24444048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natalizumab: new drug. Multiple sclerosis: risky market approval.
    Prescrire Int; 2008 Feb; 17(93):7-10. PubMed ID: 18354844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Multiple sclerosis: current therapies and future perspectives].
    Matsushita T
    Nihon Rinsho; 2011 Nov; 69(11):2077-86. PubMed ID: 22111333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 3 treatment practicalities and recommendations. MS Neurology Group of the Australian and New Zealand Association of Neurologists.
    Broadley SA; Barnett MH; Boggild M; Brew BJ; Butzkueven H; Heard R; Hodgkinson S; Kermode AG; Lechner-Scott J; Macdonell RA; Marriott M; Mason DF; Parratt J; Reddel SW; Shaw CP; Slee M; Spies J; Taylor BV; Carroll WM; Kilpatrick TJ; King J; McCombe PA; Pollard JD; Willoughby E;
    J Clin Neurosci; 2014 Nov; 21(11):1857-65. PubMed ID: 24993136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Development of new therapies for multiple sclerosis].
    Holmøy T; Celius EG
    Tidsskr Nor Laegeforen; 2011 May; 131(8):832-6. PubMed ID: 21556088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The outlook for alemtuzumab in multiple sclerosis.
    Williams T; Coles A; Azzopardi L
    BioDrugs; 2013 Jun; 27(3):181-9. PubMed ID: 23558379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natalizumab therapy for highly active pediatric multiple sclerosis.
    Kornek B; Aboul-Enein F; Rostasy K; Milos RI; Steiner I; Penzien J; Hellwig K; Pitarokoili K; Storm van's Gravesande K; Karenfort M; Blaschek A; Meyer A; Seidl R; Debelic D; Vass K; Prayer D; Kristoferitsch W; Bayas A
    JAMA Neurol; 2013 Apr; 70(4):469-75. PubMed ID: 23420110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Current treatment of multiple sclerosis].
    Csépány T
    Lege Artis Med; 2011 Feb; 21(2):97-104. PubMed ID: 21710707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.